Skip to content

Registry of Subject Treated With ClariFix

A Prospective, Multi-Center Registry of Subjects Treated With the ClariFix Cryotherapy Device

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03739216
Acronym
SNIF
Enrollment
354
Registered
2018-11-13
Start date
2018-06-13
Completion date
2021-06-15
Last updated
2021-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Rhinitis

Brief summary

A multi-center, prospective, non-randomized, observational registry to asses the results of the ClariFix(TM) device when used to ablate unwanted tissue in the nose of subjects with chronic rhinitis.

Interventions

DEVICEClariFix

The ClariFix device is a handheld cryosurgical device which provides focal, controlled freezing to the target tissue.

Sponsors

Arrinex, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Participant is scheduled to receive treatment with the ClariFix device in accordance with the ClariFix Instructions for Use. * Participant is able to provide consent and willing to adhere to the study visit schedule.

Exclusion criteria

* Participant is scheduled to have additional treatment and/or procedures completed at the same time of treatment with the ClariFix device. * Participant is scheduled to have additional nasal or sinus treatments and/or procedures completed within 3 months of treatment with the ClariFix device.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in nasal symptom severityFollow-up visits at 6 weeks, 3, 6, 9, 12, 15, 18, 21, and 24 months post treatmentEffectiveness will be assessed by the change from baseline in nasal symptoms using the TNSS (Total Nasal Symptom Score). The TNSS is a patient-reported assessment of 4 symptom scores for rhinorrhea (runny nose), nasal congestion, nasal itching, and sneezing. Each symptom is rated on a scale of 0 (none) to 3 (severe). The symptom scores are summed to give a total TNSS score that can range from 0 to 12.

Secondary

MeasureTime frameDescription
Patient-assessed improvement in nasal symptomsFollow-up visits at 6 weeks, 3, 6, 9, 12, 15, 18, 21, and 24 months post treatmentPercentage of participants reporting their change from baseline as minimally improved, much improved, or very much improved using the Patient Global Impression of Change (PGIC) assessment. The PGIC has patients evaluate their improvement over baseline on a scale from 1 (very much improved) to 7 (very much worse).
Clinician-assessed improvement in nasal symptomsFollow-up visit at 3 months post treatmentPercentage of clinicians reporting their participants change in nasal symptoms from baseline as minimally improved, much improved, or very much improved using the Clinical Global Impression - Improvement (CGI-I) assessment. The CGI-I has clinicians rate their patient's improvement over baseline on a scale from 1 (very much improved) to 7 (very much worse).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026